Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells

Cancer Biology & Therapy
Karolina Swiatek-MachadoBozena Kaminska

Abstract

JAK (Janus kinase)/STAT (signal transducers and activators of transcription) signaling is involved in the regulation of cell growth, differentiation and apoptosis. Constitutive activation of STATs, in particular STAT3, is observed in a large number of human tumors, including gliomas and may contribute to oncogenesis by stimulating cell proliferation and preventing apoptosis, thus it emerges as a promising target for anti-cancer therapy. To investigate the therapeutic potential of blocking STAT3 in glioma cells a set of small synthetic molecules - caffeic acid derivatives, structurally related to AG490 was screened for its ability to inhibit STAT3. Inhibitor 2 (E)-2-cyano-N-[(S)-1-phenylethyl]-3-(pyridin-2-yl)acrylamide was the most effective in inhibition of JAK/STAT3 signaling and at doses ≥ 25 μM significantly reduced the level of phosphorylated JAK1, JAK2 and STAT3 (at Tyr705) and downregulated the expression of known STAT3 targets. In treated cells we observed rapid detachment and rounding of cells associated with reduction of focal adhesion kinase phosphorylation and activity, followed by upregulation of phosphorylated p38, JNK and ERK1/2 levels. Accumulation of cells with fragmented DNA, increases of the cleaved caspase 3...Continue Reading

References

Apr 11, 2002·Nature Cell Biology·Cindy K Miranti, Joan S Brugge
Apr 5, 2003·Molecular and Cellular Neurosciences·Malgorzata Zawadzka, Bozena Kaminska
Jul 29, 2003·Proceedings of the National Academy of Sciences of the United States of America·John D Storey, Robert Tibshirani
Sep 19, 2003·BMC Cancer·Liza KonnikovaBrent H Cochran
Jun 4, 2004·Nature Biotechnology·Zhijin Wu, Rafael A Irizarry
Sep 29, 2004·Cellular Signalling·Aleksandra Ellert-MiklaszewskaLiliana Konarska
Oct 6, 2004·Genome Biology·Robert C GentlemanJianhua Zhang
Oct 8, 2004·Expert Opinion on Therapeutic Targets·James Turkson
Feb 3, 2005·Nature Reviews. Molecular Cell Biology·Satyajit K MitraDavid D Schlaepfer
Mar 23, 2005·Lancet·E Joanna BaxterUNKNOWN Cancer Genome Project
Jun 28, 2005·Journal of Neuropathology and Experimental Neurology·Hiroko Ohgaki, Paul Kleihues
Aug 3, 2005·Nature Reviews. Cancer·Gordon W McLeanMargaret C Frame
Aug 4, 2005·Bioinformatics·Claire L Wilson, Crispin J Miller
Oct 22, 2005·The Journal of Biological Chemistry·Judith StaerkStefan N Constantinescu
Nov 1, 2005·Cancer Metastasis Reviews·Peter J Reddig, Rudy L Juliano
Jun 28, 2006·The Journal of Pharmacology and Experimental Therapeutics·Shougang Zhuang, Rick G Schnellmann
Nov 14, 2006·Bioinformatics·S Falcon, R Gentleman
Jan 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David S ZieglerMark W Kieran
Feb 9, 2008·Genes & Development·Núria de la IglesiaAzad Bonni
Mar 4, 2008·Molecular Cancer Research : MCR·Corina BorghoutsBernd Groner
Mar 6, 2008·Neoplasia : an International Journal for Oncology Research·Hua XiongJing-Yuan Fang
Jun 6, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Núria de la IglesiaAzad Bonni
Aug 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emily C BrantleyEtty N Benveniste
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hui-Wen LoFrancis Ali-Osman
Nov 8, 2008·Annals of the New York Academy of Sciences·Sith Sathornsumetee, Jeremy N Rich
Nov 11, 2008·Recent Patents on CNS Drug Discovery·Amy B Heimberger, Waldemar Priebe
Jan 27, 2009·Cancer Metastasis Reviews·Jihe Zhao, Jun-Lin Guan
Jul 16, 2009·Current Molecular Medicine·Núria de la IglesiaAzad Bonni
Dec 17, 2009·Expert Opinion on Therapeutic Targets·Joerg SchwockDavid W Hedley

❮ Previous
Next ❯

Citations

Dec 5, 2012·BMC Medical Genomics·Ahmed SadequeSandra L Rodriguez-Zas
May 10, 2013·PLoS Computational Biology·Janusz M Bujnicki, Jerzy Tiuryn
Mar 26, 2013·Biochimica Et Biophysica Acta·Marcin MieleckiNicole LaRonde-LeBlanc
Aug 28, 2015·International Journal of Molecular Medicine·Rong-Jing ZhouWen-Hua Wang
Jan 7, 2014·Biochimica Et Biophysica Acta·Kodappully Sivaraman SiveenAnupam Bishayee
Sep 24, 2013·JAK-STAT·Celine S NicolasStephane Peineau
Aug 26, 2014·Journal of Biomedical Informatics·Dmitriy ShinChi-Ren Shyu
May 21, 2019·Frontiers in Pharmacology·Jatin Sharma, Joseph Larkin
Aug 14, 2020·Experimental & Molecular Medicine·Iwona Anna CiechomskaJakub Mieczkowski
Aug 6, 2020·Frontiers in Oncology·Maria Anele RomeoMara Cirone
Aug 16, 2018·Frontiers in Oncology·Emira Bousoik, Hamidreza Montazeri Aliabadi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.